SPOT-MAS is a non-invasive, multi-cancer early detection test that analyzes circulating tumor DNA (ctDNA) in the blood. It utilizes next-generation sequencing (NGS) and artificial intelligence (AI) technologies to identify early signs of several common and aggressive cancers from a single blood sample.

Early detection of cancer significantly improves treatment outcomes. Many cancers detected at an early stage have a greater chance of successful treatment, while late-stage diagnoses often lead to poorer prognoses.

The SPOT-MAS test is designed to detect early signs of 10 major cancer types that collectively account for approximately 70% of global cancer mortality:

• Lung cancer (including both small cell and non-small cell varieties)
• Breast cancer
• Colorectal cancer
• Stomach cancer
• Liver and biliary tract cancer
• Uterine cancer
• Esophageal cancer
• Ovarian cancer
• Pancreatic cancer
• Head and neck cancers

The SPOT-MAS test is appropriate for both men and women. It’s particularly valuable for detecting these cancers at early stages when treatment options are more effective and survival rates are significantly higher.

The test requires just one blood draw during your healthcare visit. The blood sample is then analyzed for ctDNA that may indicate the presence of cancer.

The SPOT-MAS test demonstrates strong clinical accuracy backed by extensive studies involving over 11,000 participants:

• Sensitivity: 78.1% overall (65.2% for early stages, 88.3% for Stage IIIA)
• Specificity: 99.8% (extremely low false positive rate)
• Positive Predictive Value: 58.1% (higher in males at 81.0%)
• Negative Predictive Value: 99.9% (high confidence when results are negative)
• Tissue Origin Accuracy: 84.0% when cancer is detected

These metrics reflect the test’s reliability as a screening tool. Positive results require follow-up diagnostic procedures to confirm cancer presence.

The test is recommended for adults over the age of 40. It is particularly advised for individuals at higher risk for cancer due to factors such as:

• Heavy smoking (20 pack-year history)
• Heavy drinking (15 cans of beer per week for men, 8 for women)
• Hereditary risks (e.g., positive tests for genes like BRCA1, BRCA2, TP53)
• Liver diseases (e.g., Hepatitis B or C)
• Familial history of cancers

While the primary demographic is adults over 40, younger individuals with specific high-risk factors may also be eligible for testing.

If a ctDNA signal associated with tumor cells is detected, further testing such as imaging studies will be required to confirm the presence of cancer. Your doctor will guide you through the necessary next steps.

If the test returns a negative result indicating no ctDNA signal, it suggests that cancer is not detected at that time. However, it is essential to continue regular screenings and consult with your doctor regarding any concerning symptoms.

It is recommended to have the SPOT-MAS test annually or as advised by your doctor, particularly if you have risk factors for cancer.

SPOT-MAS is a screening tool that can complement existing cancer screening programs. It is not a replacement and should be used alongside other recommended tests and screenings.

To schedule your SPOT-MAS test, you can make an appointment directly by clicking on the “Book Now” button.

We’re open Monday to Saturday at both of our convenient locations:

Orchard
HOP Medical Centre @ Palais Renaissance
390 Orchard Rd, #11-03/04, Singapore 238871

Tampines
HOP Medical Centre @ CPF Tampines Building
1 Tampines Central 5, #07-04/05, Singapore 529508

Prefer to speak with us?

Please contact the respective medical centres to book your appointment:
Orchard – 6589 0009 | Tampines – 6589 0002